The Vanda Board once more evaluated all points of Vanda’s enterprise in opposition to the unsolicited proposals and decided that the proposals are opportunistic makes an attempt to buy the Firm’s shares at a reduction to Vanda’s intrinsic worth. The Board’s prior evaluation of the corporate’s medical growth pipeline, increasing business presence and vital money steadiness stays unchanged. The Board additionally reached the identical conclusion because it reached beforehand concerning the speculative nature of the CVRs given the uncertainty surrounding the achievement of the business milestones beneath FP’s administration.
The Board and administration group stay assured that Vanda’s sturdy income, sturdy money place and environment friendly operations place the Firm effectively for vital long-term progress and worth creation far in extra of the consideration provided by Cycle Group and FP.
There is no such thing as a motion for shareholders to take presently.
About Vanda Prescribed drugs Inc.
Vanda is a number one international biopharmaceutical firm targeted on the event and commercialization of modern therapies to handle excessive unmet medical wants and enhance the lives of sufferers. For extra on Vanda Prescribed drugs Inc., please go to www.vandapharma.com and observe us on X @vandapharma.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Numerous statements on this press launch, together with, however not restricted to, statements concerning the Board’s evaluation of the Cycle Group and FP proposals and the boldness that the Board and administration group have within the Firm’s long-term prospects for progress and worth creation, are “forward-looking statements” beneath the securities legal guidelines. All statements apart from statements of historic truth are statements that might be deemed forward-looking statements. Ahead-looking statements are based mostly upon present expectations and assumptions that contain dangers, adjustments in circumstances and uncertainties. Due to this fact, no assurance may be provided that the outcomes or developments anticipated by Vanda will probably be realized or, even when considerably realized, that they may have the anticipated penalties to, or results on, Vanda. Ahead-looking statements on this press launch needs to be evaluated along with the assorted dangers and uncertainties that have an effect on Vanda’s enterprise and market, significantly these recognized within the “Cautionary Notice Relating to Ahead-Trying Statements”, “Threat Components” and “Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations” sections of Vanda’s most up-to-date Annual Report on Kind 10-Ok, as up to date by Vanda’s subsequent Quarterly Studies on Kind 10-Q, Present Studies on Kind 8-Ok and different filings with the U.S. Securities and Trade Fee, which can be found at www.sec.gov.
All written and verbal forward-looking statements attributable to Vanda or any individual performing on its behalf are expressly certified of their entirety by the cautionary statements contained or referred to herein. Vanda cautions buyers to not rely too closely on the forward-looking statements Vanda makes or which can be made on its behalf. The knowledge on this press launch is supplied solely as of the date of this press launch, and Vanda undertakes no obligation, and particularly declines any obligation, to replace or revise publicly any forward-looking statements, whether or not because of new info, future occasions or in any other case, besides as required by regulation.
Company Contact:
Vanda Prescribed drugs Inc.
202-734-3400
[email protected]
[email protected]